$TECH · BIO-TECHNE Corp
Bio-Techne filed its Q1 FY2027 10-Q (quarter ended September 30, 2026). Net sales rose 4.6% to $299.7M from $286.6M, with organic revenue up 7%. GAAP net earnings fell to $28.3M ($0.18 diluted EPS) from $38.2M ($0.24), as operating income declined to $36.6M from $47.7M on higher SG&A and R&D. Gross margin held flat at 65.6%. The filing confirms the pending Merck KGaA acquisition, approved by shareholders on September 23, 2026, expected to close late 2026 or early 2027.
- Net sales $299.7M, up 4.6% YoY; organic revenue up 7%.
- GAAP diluted EPS $0.18 vs $0.24 prior year; net earnings $28.3M vs $38.2M.
- Operating income fell to $36.6M from $47.7M on higher SG&A ($133.7M) and R&D ($26.3M).
- Gross margin flat at 65.6%; adjusted gross margin 69.3% vs 70.2%.
- Shareholders approved Merck KGaA merger on Sept 23, 2026; close expected late 2026/early 2027.
Markets closed — no regular-session reaction yet; extended-hours move not captured here.
Earnings show margin compression while the company operates under a pending Merck KGaA acquisition, making the merger close the key investor catalyst.
Life-science tools peer; results reflect the pending takeout by Merck KGaA, which caps standalone trading dynamics.
Merger closing remains subject to customary conditions and could be delayed; Wilson Wolf forward contract may require ~$1B payment if second revenue/EBITDA milestone is hit.